807 related articles for article (PubMed ID: 31011884)
1. Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders.
Raikwar SP; Kikkeri NS; Sakuru R; Saeed D; Zahoor H; Premkumar K; Mentor S; Thangavel R; Dubova I; Ahmed ME; Selvakumar GP; Kempuraj D; Zaheer S; Iyer SS; Zaheer A
J Neuroimmune Pharmacol; 2019 Dec; 14(4):608-641. PubMed ID: 31011884
[TBL] [Abstract][Full Text] [Related]
2. Utilization of the CRISPR-Cas9 Gene Editing System to Dissect Neuroinflammatory and Neuropharmacological Mechanisms in Parkinson's Disease.
Luo J; Padhi P; Jin H; Anantharam V; Zenitsky G; Wang Q; Willette AA; Kanthasamy A; Kanthasamy AG
J Neuroimmune Pharmacol; 2019 Dec; 14(4):595-607. PubMed ID: 30879240
[TBL] [Abstract][Full Text] [Related]
3. A Broad Application of CRISPR Cas9 in Infectious, Inflammatory and Neurodegenerative Diseases.
Pahan K
J Neuroimmune Pharmacol; 2019 Dec; 14(4):534-536. PubMed ID: 31782056
[TBL] [Abstract][Full Text] [Related]
4. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases.
Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
Neurochem Int; 2018 Jan; 112():187-196. PubMed ID: 28732771
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases.
Kuruvilla J; Sasmita AO; Ling APK
Neurol Sci; 2018 Nov; 39(11):1827-1835. PubMed ID: 30076486
[TBL] [Abstract][Full Text] [Related]
6. Applications of CRISPR-Cas9 in Alzheimer's Disease and Related Disorders.
De Plano LM; Calabrese G; Conoci S; Guglielmino SPP; Oddo S; Caccamo A
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955847
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases.
Karimian A; Gorjizadeh N; Alemi F; Asemi Z; Azizian K; Soleimanpour J; Malakouti F; Targhazeh N; Majidinia M; Yousefi B
Life Sci; 2020 Oct; 259():118165. PubMed ID: 32735884
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9 Technology as a Modern Genetic Manipulation Tool for Recapitulating of Neurodegenerative Disorders in Large Animal Models.
Barazesh M; Mohammadi S; Bahrami Y; Mokarram P; Morowvat MH; Saidijam M; Karimipoor M; Kavousipour S; Vosoughi AR; Khanaki K
Curr Gene Ther; 2021; 21(2):130-148. PubMed ID: 33319680
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders.
Guan L; Han Y; Yang C; Lu S; Du J; Li H; Lin J
Mol Neurobiol; 2022 Feb; 59(2):968-982. PubMed ID: 34813019
[TBL] [Abstract][Full Text] [Related]
10. Futuristic approach to cancer treatment.
Malik D; Mahendiratta S; Kaur H; Medhi B
Gene; 2021 Dec; 805():145906. PubMed ID: 34411650
[TBL] [Abstract][Full Text] [Related]
11. Epigenome Editing in the Brain.
Bashtrykov P; Jeltsch A
Adv Exp Med Biol; 2017; 978():409-424. PubMed ID: 28523558
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9-mediated genome editing: From basic research to translational medicine.
Jacinto FV; Link W; Ferreira BI
J Cell Mol Med; 2020 Apr; 24(7):3766-3778. PubMed ID: 32096600
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Based Genome-Editing Tools for Huntington's Disease Research and Therapy.
Qin Y; Li S; Li XJ; Yang S
Neurosci Bull; 2022 Nov; 38(11):1397-1408. PubMed ID: 35608753
[TBL] [Abstract][Full Text] [Related]
14. Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review.
Ebrahimi V; Hashemi A
Gene; 2020 Aug; 753():144813. PubMed ID: 32470504
[TBL] [Abstract][Full Text] [Related]
15. A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System.
Bellizzi A; Ahye N; Jalagadugula G; Wollebo HS
J Neuroimmune Pharmacol; 2019 Dec; 14(4):578-594. PubMed ID: 31512166
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas: An intriguing genomic editing tool with prospects in treating neurodegenerative diseases.
Rahman S; Datta M; Kim J; Jan AT
Semin Cell Dev Biol; 2019 Dec; 96():22-31. PubMed ID: 31102655
[TBL] [Abstract][Full Text] [Related]
17. Understanding the Potential of Genome Editing in Parkinson's Disease.
Arango D; Bittar A; Esmeral NP; Ocasión C; Muñoz-Camargo C; Cruz JC; Reyes LH; Bloch NI
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502143
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9 Gene Editing: From Basic Mechanisms to Improved Strategies for Enhanced Genome Engineering In Vivo.
Salsman J; Masson JY; Orthwein A; Dellaire G
Curr Gene Ther; 2017; 17(4):263-274. PubMed ID: 29173169
[TBL] [Abstract][Full Text] [Related]
19. CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics.
Sen T; Thummer RP
Neurotox Res; 2022 Oct; 40(5):1597-1623. PubMed ID: 36044181
[TBL] [Abstract][Full Text] [Related]
20. CRISPR: History and perspectives to the future.
Kozovska Z; Rajcaniova S; Munteanu P; Dzacovska S; Demkova L
Biomed Pharmacother; 2021 Sep; 141():111917. PubMed ID: 34328110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
